Related Experiment Videos

[Risk of gastrointestinal bleeding with aspirin and platelet antiaggregants]

Gianfranco Nardulli1, Angel Lanas

  • 1Instituto Aragonés de Ciencias de la Salud, Servicio de Aparato Digestivo, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.

Gastroenterologia Y Hepatologia
|January 29, 2009
PubMed

Insights

Low-dose aspirin prevents cardiovascular events but can cause gastrointestinal issues. Identifying patient risk factors and using protective strategies like proton pump inhibitors can minimize these adverse effects.

Area of Science:

  • Pharmacology
  • Cardiology
  • Gastroenterology

Background:

  • Aspirin is a common antiplatelet agent for preventing thrombotic cardiovascular disease.
  • Low-dose aspirin (75-325 mg/day) inhibits cyclooxygenase-1 (COX-1), leading to gastrointestinal adverse effects.
  • Alternative antiplatelet drugs like clopidogrel and ticlopidine offer different mechanisms of action, avoiding COX-1 inhibition.

Purpose of the Study:

  • To optimize the use of antiplatelet agents, including low-dose aspirin, by minimizing gastrointestinal adverse effects.
  • To identify key risk factors associated with gastrointestinal adverse effects in patients using antiplatelet therapy.
  • To inform individualized patient management strategies for reducing gastrointestinal risks.

Main Methods:

  • Review of existing literature on antiplatelet drug mechanisms and gastrointestinal adverse effects.
  • Analysis of risk factors contributing to gastrointestinal complications in patients on antiplatelet therapy.
  • Evaluation of protective strategies, including proton pump inhibitors and Helicobacter pylori eradication.

Main Results:

  • Gastrointestinal adverse effects are a significant concern with aspirin and other antiplatelet agents.
  • Risk factors for gastrointestinal adverse effects include advanced age, concurrent use of anticoagulants or NSAIDs, history of peptic ulcer disease, and H. pylori infection.
  • Proton pump inhibitors and H. pylori eradication are effective in mitigating gastrointestinal risks.

Conclusions:

  • Individualized patient management is crucial for optimizing antiplatelet therapy and minimizing gastrointestinal harm.
  • Recognizing and addressing risk factors can significantly improve patient outcomes.
  • Prophylactic measures, such as proton pump inhibitors, are beneficial even in high-risk patients.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.